Pinnacle Associates LTD Incyte Corp Transaction History

Pinnacle Associates LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 30, 2024	BUY	$51.18 - $63.75 $476,229 - $593,193	9,305 Added 17.47%	62,579 $3.79 Million
Q1 2024 Apr 26, 2024	BUY	$56.55 - $66.59 $3.01 Million - $3.55 Million	53,274 New	53,274 $3.04 Million
Q2 2019 Aug 05, 2019	SELL	$73.52 - $88.7 $1.67 Million - $2.02 Million	-22,750 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$63.56 - $88.17 $193,858 - $268,918	3,050 Added 15.48%	22,750 $1.96 Million
Q4 2018 Feb 05, 2019	BUY	$58.5 - $69.94 $914,062 - $1.09 Million	15,625 Added 383.44%	19,700 $1.25 Million
Q3 2018 Nov 13, 2018	BUY	$61.75 - $74.23 $20,068 - $24,124	325 Added 8.67%	4,075 $282,000
Q2 2018 Aug 08, 2018	BUY	$60.85 - $83.98 $6,085 - $8,398	100 Added 2.74%	3,750 $251,000
Q1 2018 May 11, 2018	BUY	$83.06 - $100.98 $116,284 - $141,372	1,400 Added 62.22%	3,650 $304,000
Q4 2017 Feb 12, 2018	BUY	$93.56 - $116.6 $13,004 - $16,207	139 Added 6.58%	2,250 $213,000
Q2 2017 Aug 09, 2017	BUY	N/A	2,111	2,111 $266,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Pinnacle Associates LTD, based on Form 13F filings with the SEC.

Stay updated on Pinnacle Associates LTD with notifications on news.